Can You Sue a Drug Manufacturer for Failing to Develop a Safer Alternative? The Gilead Tenofovir Decision
The California Supreme Court rejected the “duty to innovate” theory in the Gilead TDF/TAF litigation — a major shift for thousands of California drug injury claims. Learn what the ruling actually decided, why Brown v. Superior Court still shapes prescription drug liability, which theories still work (failure to warn, negligent design, negligent surveillance, fraudulent concealment), how the two-year deadline under CCP § 335.1 and the six-month government claim deadline apply, and what evidence decides these cases in Los Angeles.
Read the Full Guide →